Fierce Pharma

DECEMBER 2, 2022

With buyout on Horizon, Amgen and Sanofi eye cash plays for rare disease drug maker. fkansteiner. Fri, 12/02/2022 - 09:51.

305

305

PharmaVoice

NOVEMBER 28, 2022

After nearly five years, the homicide case involving pharma billionaires continues to perplex investigators.

Pharma 144

Pharma 144

MedCity News

DECEMBER 1, 2022

Thanks to the convergence of cloud technologies, AI, and refined lung data, we are in a new era for those with chronic lung disease. In this new world, lung intelligence provides fast, precision measures of treatment efficacy so new drugs can blaze through the trial pipeline.

Biopharma 134

Biopharma 134

Pharmaceutical Technology

NOVEMBER 29, 2022

The National Health Service (NHS) in England, UK, has expedited the rollout of Bayer ’s new life-extending drug, darolutamide, to treat the most advanced kinds of prostate cancer that have spread to other body parts. With the latest development, NHS will become the first healthcare system in Europe to offer this drug to prostate cancer patients. Nearly 9,000 men with prostate cancer will be eligible to receive this treatment.

Healthcare 118

Healthcare Healthcare Patients Medicine 118

Advertisement

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

Sales Management

Fierce Pharma

NOVEMBER 28, 2022

Genentech starts phase 2 trial to optimize delivery of eye disease cell therapy. ntaylor. Mon, 11/28/2022 - 10:11.

299

299

PharmaVoice

DECEMBER 1, 2022

Why South Rampart Pharma’s novel new molecule could be a key to solving the global pain epidemic.

Pharma 122

Pharma 122

European Pharmaceutical Review

NOVEMBER 29, 2022

A £2.9 million, UK-wide adaptive platform trial (APT) has been launched to find effective treatments for people hospitalised with severe flu for the first time, testing multiple options simultaneously in thousands of people then modifying treatments quickly. The research aims to find treatments that reduce deaths from flu and prevent patients needing intensive care.

Medicine 115

Medicine Recruitment Consulting Healthcare 115

Fierce Pharma

DECEMBER 1, 2022

With FDA nod for its fecal microbiome therapy, Ferring becomes No. 1 in No. 2. kdunleavy. Thu, 12/01/2022 - 10:14.

FDA 290

FDA 290

pharmaphorum

DECEMBER 1, 2022

Lack of access, strict regulations, and demanding schedules have made it extremely difficult for patients to participate in clinical trials. A 2018 NIH survey found that patients felt clinical trial participation to be inconvenient and burdensome, and nearly half (49.0%) said it disrupted their daily routine. In 2021, a CISCRIP Perceptions and Insights Study reported more disruption to daily routines compared to previous years, citing length of visits, travel, and diagnostic tests as top burdens

Patients 111

Patients Transportation Retail Recruitment 111

MedCity News

DECEMBER 2, 2022

From streamlining long-held manual processes to creating entirely new diagnostic devices, new tech is cropping up all over the medtech industry—resulting in a real-world impact on patients’ quality of life.

Patients 130

Patients 130

Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.

The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven

Patients

Pharmaceutical Technology

NOVEMBER 29, 2022

AstraZeneca has signed an agreement for the acquisition of all outstanding equity of clinical-stage biotechnology firm Neogene Therapeutics in a deal totalling up to $320m. Neogene focuses on discovering, developing and producing next-generation T-cell receptor therapies (TCR-Ts) that provide a new cell therapy approach for fighting cancer. TCR-Ts can detect intracellular targets such as cancer-specific mutations to unlock targets which were not accessible earlier using cell therapies.

Leads 111

Leads Manufacturing Patients Pharmaceutical 111

Fierce Pharma

DECEMBER 1, 2022

Eli Lilly dumps Innovent's PD-1 after FDA rebuff, nixing high-profile Chinese cancer drug. aliu. Thu, 12/01/2022 - 15:03.

FDA 279

FDA 279

pharmaphorum

NOVEMBER 28, 2022

According to a report by the Office of Health Economics (OHE), commissioned by the Association of the British Pharmaceutical Industry (ABPI), immediate action must be taken by governments, health systems, and companies to secure the era of green pharmaceuticals. ‘Supporting the era of green pharmaceuticals in the UK’ highlights that, while Britain can play a leading role in the sustainability agenda for pharmaceuticals, action must also be taken on a global scale to ensure impact.

Pharmaceutical 110

Pharmaceutical Government Healthcare Healthcare 110

MedCity News

NOVEMBER 29, 2022

Nvidia unveiled new tools designed to make it easier for hospitals to integrate AI models related to medical imaging into their clinical workflows. The tools have been adopted by major cloud infrastructure providers, as well as healthcare providers and AI software companies. Some of these include Cincinnati Children’s Hospital, University of California San Francisco, England’s National Health Service and Qure.ai.

Healthcare Provider 130

Healthcare Provider Medical Healthcare Healthcare 130

Advertisement

Pharmaceutical Technology

NOVEMBER 29, 2022

For several decades, researchers have been investigating the role of ketamine in treating depression. Now, efforts are underway to study ketamine’s effects in Parkinson’s disease, fibromyalgia, and Rett syndrome. On November 14, the Canadian developer PharmaTher announced positive data from a Phase I/II study where ketamine was used to treat levodopa-induced dyskinesia in Parkinson’s disease.

Side effects 110

Side effects Pharmaceutical Patients Medicine 110

Fierce Pharma

DECEMBER 1, 2022

PureTech readies oral CBD capsule for clinic to challenge Jazz’s Epidiolex. ntaylor. Thu, 12/01/2022 - 11:05.

277

277

PharmaTimes

NOVEMBER 29, 2022

Bill & Melinda Gates Foundation grant will boost potential of nanoparticle-formulated doggybone DNA

107

107

MedCity News

DECEMBER 2, 2022

Health system leaders believe that improving patient access should be their top priority when strategically planning for 2023, according to a new report from the KLAS Research and UPMC’s Center for Connected Medicine. To improve patient access, respondents agreed that their health systems will need to make changes in three key areas — people, process and technology.

Patients 128

Patients Medicine 128

Advertisement

Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.

Safety

European Pharmaceutical Review

DECEMBER 2, 2022

Pfizer Inc. has announced it will invest over €1.2 billion in its manufacturing site in Grange Castle , Dublin, the company’s biggest expansion investment to date in Ireland. A new facility will be built on the site premises, doubling the capacity for biologics manufacturing at the facility. It is anticipated a further 400-500 roles will be created, bringing the total Pfizer employees in Ireland to around 5,500.

Manufacturing 105

Manufacturing Medicine Networking Medical 105

Fierce Pharma

DECEMBER 2, 2022

UPDATED: GSK, with new trial win, looks to expand PD-1 Jemperli in endometrial cancer. zbecker. Fri, 12/02/2022 - 11:22.

264

264

PharmaTimes

NOVEMBER 30, 2022

Phase 3 research shows that Alzheimer’s disease treatment meets primary and secondary endpoints

106

106

MedCity News

NOVEMBER 28, 2022

Cincor Pharma drug baxdrostat failed its Phase 2 test, falling short of the goal of reducing blood pressure in patients with uncontrolled hypertension. But results in a subgroup of patients showed double-digit declines, which the company said could inform the design of a Phase 3 clinical trial.

Pharma 128

Pharma Patients Biopharma 128

Advertisement

Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten

Sales

pharmaphorum

NOVEMBER 29, 2022

NeoImmuneTech, Inc. CEO: Dr Se Hwan Yang, PhD. Headquarters: Rockville, MD, USA (2400 Research Blvd., Suite 250, Rockville, MD 20850). Locations: 3 (US HQ, Korea office, Korea R&D center). Number of employees: 90+ (as of Oct. 31, 2022). Main asset: NT-I7 (efineptakin alfa), a long-acting human IL-7. Number of on-going clinical trials: 14. Creation: Jan. 29, 2014.

Safety 105

Safety Patients Engineering Recruitment 105

Fierce Pharma

NOVEMBER 30, 2022

UK regulators warn of ocular side effects after treatment with Sanofi's Dupixent. zbecker. Wed, 11/30/2022 - 10:55.

Side effects 264

Side effects 264

Pharmaceutical Technology

DECEMBER 1, 2022

The US Food and Drug Administration (FDA) has granted approval for Ferring Pharmaceuticals’ faecal microbiota product, Rebyota, to prevent Clostridioides difficile infection (CDI) recurrence in people aged 18 years and above. A live biotherapeutic, Rebyota is intended for usage following the completion of antibiotic treatment. Rebyota’s safety and efficacy were analysed in the largest trial programme in the microbiome-based therapeutics field, including five trials enrolling over 1,000 subjects.

Food and Drug Administration 105

Food and Drug Administration FDA Food Pharmaceutical 105

MedCity News

DECEMBER 2, 2022

Lumen sells a handheld device that measures users’ metabolism through breath and connects to an app that helps track goals and provides nutrition coaching. The funding round was led by Pitango Venture Capital, and included participation from Hanwha Group and Resolute Ventures.

124

124

Advertiser: ZoomInfo

Marketing technology is essential for B2B marketers to stay competitive in a rapidly changing digital landscape — and with 53% of marketers experiencing legacy technology issues and limitations, they’re researching innovations to expand and refine their technology stacks. To help practitioners keep up with the rapidly evolving martech landscape, this special report will discuss: How practitioners are integrating technologies and systems to encourage information-sharing between departments and pr

Competition

pharmaphorum

NOVEMBER 27, 2022

Supply chain issues have been rife in pharmaceuticals for a while, but current socio-economic challenges such as the conflict in Ukraine and the COVID-19 pandemic have led to extended wait times and higher prices for thousands of products. Incidents such as the hormone replacement therapy drug shortage in early 2022 have shown the damaging impact supply chain issues can have on people who depend on these drugs.

Pharma 105

Pharma Safety Pharmaceutical Manufacturing 105

Fierce Pharma

DECEMBER 1, 2022

Roche, having shared data with regulators, unwraps results of subcutaneous Tecentriq phase 3 trial. ntaylor. Thu, 12/01/2022 - 09:45.

264

264

Pharmaceutical Technology

NOVEMBER 28, 2022

C4X Discovery (C4XD) and AstraZeneca have entered an exclusive global licensing agreement worth up to $402m to develop oral therapy to treat inflammatory and respiratory ailments. The deal has been signed to develop the C4X NRF2 Activator programme for these ailments. Under the agreement, AstraZeneca will be responsible for the development and marketing of oral therapy for inflammatory and respiratory diseases with a key focus on chronic obstructive pulmonary disease (COPD).

Pharmaceutical 105

Pharmaceutical Marketing Leads 105

MedCity News

DECEMBER 2, 2022

Check out new developments from Medvantx, Medisafe, Medical Informatics Corp., Journey Biosciences, and GSR Ventures.

Healthcare 124

Healthcare Healthcare Medical 124

Advertisement

Distribution